Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 7/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074650 | 1.00 | DYRK1B (0.40) | DYRK1BCNR1NR4A2TRPV4AXL | |
| SCHEMBL11729538 | 0.86 | DYRK1B (0.40) | DYRK1BCNR1NR4A2AXLPRKCI | |
| SCHEMBL26087032 | 0.86 | OGA (0.42) | NR4A2TRPV4AXLPRKCIMAPT | |
| SCHEMBL265444 | 0.76 | CCNC (0.49) | DYRK1BNR4A2AXLPRKCIKDM4E | |
| SCHEMBL29691695 | 0.76 | CCNC (0.49) | DYRK1BNR4A2AXLPRKCIKDM4E | |
| SCHEMBL14690725 | 0.75 | LMNA (0.40) | TRPV4KDM4EMAPTCYP2C19 | |
| SCHEMBL30051309 | 0.75 | NR4A2 (0.66) | DYRK1BNR4A2AXLPRKCIMAPT | |
| SCHEMBL1888577 | 0.75 | NR4A2 (0.66) | DYRK1BNR4A2AXLPRKCIMAPT | |
| SCHEMBL31510523 | 0.73 | LMNA (0.56) | KDM4EL3MBTL1 | |
| SCHEMBL3649184 | 0.72 | NR4A2 (0.52) | DYRK1BNR4A2AXLPRKCIKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374928-A2 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham And Women's Hospital Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-3615538-B1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| CN-111164083-B | Novel ALK2 inhibitors and methods for inhibiting BMP signaling | 布里格姆妇女医院股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2023-01-05 | — | — | US | disclosed |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2023-01-05 | — | — | US | disclosed |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-11 | — | — | US | disclosed |
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-11 | — | — | US | disclosed |
| CN-111164083-A | Novel ALK2 inhibitors and methods for inhibiting BMP signaling | 布里格姆妇女医院股份有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3615538-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham and Women's Hospital, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200855-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BMPR2, BMP1, BMP2K | DYRK1B 1054/4885CNR1 3161/4885NR4A2 2365/4885 |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BMPR2, BMP1, BMP2K | DYRK1B 1054/4885CNR1 3161/4885NR4A2 2365/4885 |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | DYRK1B 1257/4885CNR1 3121/4885NR4A2 1962/4885 |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | DYRK1B 1257/4885CNR1 3121/4885NR4A2 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.